Improving outcomes in early prostate cancer: Part I - Adjuvant treatment

BJU International

Volumn 98, Issue 4, 2006, Pages 725-730

  Mazhar, Danish ^a   Ngan, Sarah ^a   Waxman, Jonathan ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANDROGEN; CYPROTERONE ACETATE; ESTRAMUSTINE; ETOPOSIDE; GOSERELIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HORMONAL THERAPY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT;

EID: 33748593644     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06366.x     Document Type: Short Survey

References (44)

1. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
2. Carrol PR, Lee KL, Fuks ZY et al. Cancer of the prostate. In DeVita VT, Hellman S, Rosenberg SA eds, Cancer Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott, Williams & Wilkins 2001: 1418-76
3. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 2163-72
4. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Eng J Med 2004; 351: 125-35
5. Eastham JA, Kattan MW, Scardino PT. Nomograms as predictive models. Semin Urol Oncol 2002; 20: 108-15
6. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300
7. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet 2002; 360: 103-6
8. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1988; 14: 1085-91
9. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998; 159: 2030-4
10. Pilepich MV, Caplan R, Byhardt RW et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Protocol 85-31. J Clin Oncol 1997; 15: 1013-21
11. Lawton CA, Winter K, Murray K et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-46
12. Roach M 3rd, Lu J, Pilepich MV et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Boil Phys 2000; 47: 617-27
13. Seidenfeld J, Samson DJ, Aronson N et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) 1999; i-x: 1-246
14. Pilepich MV, Winter K, John MJ et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52
15. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49: 947-56
16. Prayer-Galetti T, Zattoni F, Capizzi F et al. Disease-free survival in patients with pathologic 'C stage' prostate cancer at radical prostatectomy, submitted to adjuvant hormonal treatment. Eur Urol 2000; 38: 504, Abstract
17. Wirth M, Froehner M. A review of studies of hormonal adjuvant therapy in prostate cancer. Eur Urol 1999; 36 (Suppl. 2): 14-9
18. See WA, Wirth MP, McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002; 168: 429-35
19. Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 19-23
20. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-41
21. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results from 498 patients. Int J Radiat Oncol Biol Phys 2000; 48: 355-67
22. Kestin LL, Vicini FA, Ziaja EL, Stromberg JS, Frazier RC, Martinez AA. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 1999; 86: 1557-66
23. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002; 20: 3376-85
24. Cannon GM Jr, Walsh PC, Partin AW, Pound CR. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. Urology 2003; 62 (Suppl. 1): 2-8
25. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7
26. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997; 44: 213-21
27. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005; 23: 6992-8
28. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to radiotherapy in prostate carcinoma - long-term results of phase III RTOG study 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90
29. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Eng J Med 1999; 341: 1781-8
30. Reynolds W, Wu J, Sun L et al. Comparison of early versus late hormonal therapy (HT) Following early PSA-only recurrence (ePSAR) within the Department of Defense Center for Prostate Disease Research Database. Proc Am Soc Clin Onc 2003; 22: 392, Abstract
31. Valicenti RK, Gomella LG, Ismail M et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1999; 45: 53-8
32. Schild SE. Radiation therapy after prostatectomy: now or later? Semin Radiat Oncol 1998; 8: 132-9
33. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990; 144: 1180-4
34. Anscher MS, Prosnitz LR. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1987; 138: 1407-12
35. Paulson DF, Moul JW, Robertson JE, Walther PJ. Postoperative radiotherapy of prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1990; 143: 1178-82
36. Schild SE, Wong WW, Grado GL et al. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 1994; 69: 613-9
37. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8
38. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end-points. J Clin Oncol 1996; 14: 1756-64
39. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
40. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
41. Zelefsky MJ, Kelly WK, Scher HI et al. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol 2000; 18: 1936-41
42. Khil MS, Kim JH, Bricker LJ, Cerny JC. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy. Cancer J Sci Am 1997; 3: 289-96
43. Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A. Evaluation of adjuvant estramustine phosphate, cyclophosphamide and observation only for node positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project. Prostate 1996; 28: 51-7
44. Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000; 86: 675-80